Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

Chemistry and Pharmacology of Nicotinic Ligands Based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for Possible Use in Depression.

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

The Potent and Selective Α4β2/α6-Nicotinic Acetylcholine Receptor Partial Agonist 2-[5-[5-((s)azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol Demonstrates Antidepressive-Like Behavior in Animal Models and a Favorable ADME-tox Profile.

Identification Of Novel Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based On An Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity

Recent Developments in Novel Antidepressants Targeting Α4β2-Nicotinic Acetylcholine Receptors.

Development of Antidepressant Drugs Through Targeting Α4β2-Nicotinic Acetylcholine Receptors

Chemistry and Behavioral Studies Identify Chiral Cyclopropanes As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile.

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

Discovery of Isoxazole Analogues of Sazetidine-A As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists for the Treatment of Depression

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Chemistry, Pharmacology, and Behavioral Studies Identify Chiral Cyclopropanes As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile. Part II.

The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial

Role Ofn-Methyl-d-aspartate Receptors in Antidepressant-Like Effects of Σ1receptor Agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats

Synthesis and Biological Evaluation of Novel Triazine Derivatives as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity

Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats

Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal

[Underlying mechanisms for psychotropic effects of delta opioid receptor agonists]

Allosteric Modulation of Sigma‐1 Receptors Elicits Rapid Antidepressant Activity